277 related articles for article (PubMed ID: 15255086)
21. Evaluation of efficacy of heartworm preventive products at the FDA.
Hampshire VA
Vet Parasitol; 2005 Oct; 133(2-3):191-5. PubMed ID: 16099105
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals.
Schick A; Miller KL; Lanthier M; Dal Pan G; Nardinelli C
Drug Saf; 2017 Jun; 40(6):497-503. PubMed ID: 28342075
[TBL] [Abstract][Full Text] [Related]
23. FDA drug prescribing warnings: is the black box half empty or half full?
Wagner AK; Chan KA; Dashevsky I; Raebel MA; Andrade SE; Lafata JE; Davis RL; Gurwitz JH; Soumerai SB; Platt R
Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):369-86. PubMed ID: 16294363
[TBL] [Abstract][Full Text] [Related]
24. Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium.
Anthony M; Romero K; Malone DC; Hines LE; Higgins L; Woosley RL
Clin Pharmacol Ther; 2009 Oct; 86(4):425-9. PubMed ID: 19587643
[TBL] [Abstract][Full Text] [Related]
25. Prescription drug products; revocation of patient package insert requirements--Food and Drug Administration. Final rule.
Fed Regist; 1982 Sep; 47(173):39147-55. PubMed ID: 10258154
[TBL] [Abstract][Full Text] [Related]
26. Boxed warnings and other FDA communication tools.
Marks NS; Weiss K
Am Fam Physician; 2010 Feb; 81(3):259. PubMed ID: 20112882
[No Abstract] [Full Text] [Related]
27. Bringing greater transparency to "black box" warnings.
Buckley NA; Rossi S
Clin Toxicol (Phila); 2011 Jul; 49(6):448-51. PubMed ID: 21824055
[TBL] [Abstract][Full Text] [Related]
28. Unapproved uses of approved drugs: The physician, the package insert, and the FDA.
Pediatrics; 1978 Aug; 62(2):262-4. PubMed ID: 693165
[No Abstract] [Full Text] [Related]
29. Amendment of regulations regarding certain label statements on prescription drugs. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2002 Feb; 67(22):4904-7. PubMed ID: 11829025
[TBL] [Abstract][Full Text] [Related]
30. Drug safety labeling for doctors.
Hecht A
FDA Consum; 1979 Oct; 13(8):12-3. PubMed ID: 10309108
[TBL] [Abstract][Full Text] [Related]
31. Food and Drug Administration approval process for ophthalmic drugs in the US.
Lloyd R; Harris J; Wadhwa S; Chambers W
Curr Opin Ophthalmol; 2008 May; 19(3):190-4. PubMed ID: 18408492
[TBL] [Abstract][Full Text] [Related]
32. [Improvement of package insert CYP information for prescription drugs marketed in Japan].
Hirata-Koizumi M; Saito M; Urano T; Miyake S; Hasegawa R
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):12-8. PubMed ID: 16541745
[TBL] [Abstract][Full Text] [Related]
33. How should FDA regulate prescription drug promotion on the Internet?
Opderbeck DW
Food Drug Law J; 1998; 53(1):47-61. PubMed ID: 11795336
[TBL] [Abstract][Full Text] [Related]
34. Drug labeling; orally ingested over-the-counter drug products containing calcium, magnesium, and potassium. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2004 Mar; 69(57):13725-35. PubMed ID: 15040351
[TBL] [Abstract][Full Text] [Related]
35. FDA proposes new rules for off-label use of prescription drugs. Food and Drug Administration.
Baker R
BETA; 1998 Jul; ():8-9. PubMed ID: 11365570
[TBL] [Abstract][Full Text] [Related]
36. From off-label prescribing towards a new FDA.
Tabarrok A
Med Hypotheses; 2009 Jan; 72(1):11-3. PubMed ID: 18835103
[TBL] [Abstract][Full Text] [Related]
37. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Aug; 73(164):49603-10. PubMed ID: 18958946
[TBL] [Abstract][Full Text] [Related]
38. Rx with a dose of info.
Miller RW
FDA Consum; 1980 Nov; 14(9):22-3. PubMed ID: 10309292
[TBL] [Abstract][Full Text] [Related]
39. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action.
Wysowski DK; Nourjah P; Swartz L
Arch Intern Med; 2007 Jul; 167(13):1414-9. PubMed ID: 17620536
[TBL] [Abstract][Full Text] [Related]
40. Food and Drug Administration surveillance of dermatology-related and nondermatology-related prescription drug advertising in the USA, 2000-2003.
Cowden AL; Katz KA
Br J Dermatol; 2006 May; 154(5):950-8. PubMed ID: 16634900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
